BioSpace News Archive

PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that the first patient has been enrolled and randomized in the SHIELD I ( S urgical site H ospital acquir

Hexion Inc. (“Hexion” or the “Company”) today announced the release of its 2019 Sustainability Report highlighting the company’s efforts and accomplishments in enhancing safety, efficiency, sustainability and social responsibility.

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the company has earned a place on Boston Consulting Group’s (BCG) “The Most Innovative Companies 2020” ranking of the top 50 most innovative companies worldwide, moving up 6 spots from 2019. In its new 2020 position at number

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2, the virus causing the current global pandemic.

Aligos Therapeutics, Inc. (Aligos), a private biotechnology company focused on the development of targeted antiviral therapies directed against chronic hepatitis B (CHB), COVID-19 and therapeutics for NASH, today announced that they have entered into a collaboration and license agreement with KU Leuven, in particular its Centre for Drug Design and Discovery (CD3), a drug discovery unit and investment mechanism o

Partnership promotes on-site prevention of prescribed opioid misuse and targeted interventive treatment for patients with behavioral health needs and Substance Use Disorder, then transitions to PursueCare’s app-based at-home telehealth program.

Freedom Institute, New York’s leading independent, non-profit, outpatient, substance abuse treatment center, announces the launch of Veritus, a concierge Telehealth treatment program designed exclusively for licensed medical professionals.

Respondents with no stage awareness had less confidence in condition management, less positive HCP relationships

Syqe Medical’s randomized controlled trial demonstrates for first time that THC doses measured in micrograms relieve pain without significant side effects

marks the launch of POP-BUILDER Rx™, a powerful pharmacy analytics platform that represents a seismic shift in population health management. This new solution provides next generation analytics for hospitals, payers, self-insured employers, pharmacy benefit managers and life science organizations by applying objective, real-world pharmacy utilization data to improve outcomes and achieve a demonstrable reduction in the total cost of care.